Aurobindo Pharma calls off its acquisition of Cronus Pharma
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Lenalidomide is used to treat cancer and also some anaemia disorders
The group has a total of 320 ANDA approvals
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Nearly 6,000 patients have been treated with the drug since 2017
Subscribe To Our Newsletter & Stay Updated